US-based specialty pharmaceutical company Currax Pharmaceuticals LLC announced on Thursday that it has received approval from the US Food & Drug Administration (FDA) for a second manufacturing site for CONTRAVE, also marketed as MYSIMBA, in the European Union and European Economic Area.

The company says that this approval comes at a critical time as demand for effective obesity treatments surges worldwide and reinforces the company's commitment to continuous patient access to treatment. The approval of this second site also enhances production capacity, confirming continued patient access to CONTRAVE while reinforcing the company's broader commitment to obesity research and treatment.

Currax says that it is investing in manufacturing and advancing clinical research, and is working to provide reliable, evidence-based treatment options for patients and healthcare providers.

Aaron Chesnut, vice president Technical Operations, said, 'At Currax, we are steadfast in our commitment to ensuring that patients and healthcare providers have uninterrupted access to CONTRAVE. Securing a second FDA-approved drug product manufacturing site enhances our ability to respond to shifting industry conditions and safeguards against external factors that could impact production and distribution.'